A phase I and pharmacokinetic study of oral administration of SU5416 in patients with advanced solid tumors
Salzberqg, M.; Pless, M.; Rochlitz, C.; Scigalla, P.; Herrmann, R.
EJC Suppls 1(5): S172
2003
DOI: 10.1016/s1359-6349(03)90601-x
Accession: 034313738
PDF emailed within 0-6 h: $19.90
Related References
Ueda, Y.; Shimoyama, T.; Murakami, H.; Yamamoto, N.; Yamada, Y.; Arioka, H.; Tamura, T. 2011: Phase i and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors Cancer ChemoTherapy and Pharmacology 67(5): 1101-1109Tolcher, A.; Cohen, R.B.; Benettaib, B.; Frenz, L.; Gianella-Borradori, A.; Calvo, E. 2016: Phase I and pharmacokinetic trial of oral administration of CYC682, a novel 2' deoxycytidine type anti-metabolite pro-drug, in patients with advanced solid tumors or lymphoma Journal of Clinical Oncology 23(16_Suppl): 2026-2026
van Groeningen, C.J.; Peters, G.J.; Schornagel, J.H.; Gall, H.; Noordhuis, P.; de Vries, M.J.; Turner, S.L.; Swart, M.S.; Pinedo, H.M.; Hanauske, A.R.; Giaccone, G. 2000: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(14): 2772-2779
Heath, E.I.; Forman, K.; Malburg, L.; Gainer, S.; Suttle, A.B.; Adams, L.; Ball, H.; LoRusso, P. 2012: A phase i pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors Investigational new Drugs 30(4): 1566-1574
Doi, T.; Tamura, K.; Tanabe, Y.; Yonemori, K.; Yoshino, T.; Fuse, N.; Kodaira, M.; Bando, H.; Noguchi, K.; Shimamoto, T.; Ohtsu, A. 2015: Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors Cancer ChemoTherapy and Pharmacology 76(2): 409-416
Eder, J.P.; Hidalgo, M.; Mendelson, D.; Ryan, P.D.; Arun, B.; Lovalvo, J.; Eiseman, I.; Olson, S.; Lenehan, P.; Garland, L.L. 2016: A phase I clinical and pharmacokinetic (PK) study of oral CI-1033 + docetaxel (DOC) in the treatment of patients with advanced solid tumors Journal of Clinical Oncology 23(16_Suppl): 3111-3111
Garland, L.L.; Hidalgo, M.; Mendelson, D.S.; Ryan, D.P.; Arun, B.K.; Lovalvo, J.L.; Eiseman, I.A.; Olson, S.C.; Lenehan, P.F.; Eder, J.P. 2006: A phase i clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12(14 Part 1): 4274-4282
Panasci, L.; Stinson, S.F.; Melnychuk, D.; Sandor, V.; Miller, W.H.; Batist, G.; Patenaude, F.; Bangash, N.; Panarello, L.; Alaoui-Jamali, M.; Sausville, E. 2003: SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase i and pharmacokinetic study in patients with advanced solid tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21(2): 232-240
Dupont, J.; Bienvenu, B.; Aghajanian, C.; Pezzulli, S.; Sabbatini, P.; Vongphrachanh, P.; Chang, C.; Perkell, C.; Ng, K.; Passe, S.; Breimer, L.; Zhi, J.; DeMario, M.; Spriggs, D.; Soignet, S.L. 2004: Phase i and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 22(16): 3366-3374
Fakih, M.G.; Trump, D.L.; Muindi, J.R.; Black, J.D.; Bernardi, R.J.; Creaven, P.J.; Schwartz, J.; Brattain, M.G.; Hutson, A.; French, R.; Johnson, C.S. 2007: A phase i pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(4): 1216-1223
Rugo, H.S.; Herbst, R.S.; Liu, G.; Park, J.W.; Kies, M.S.; Steinfeldt, H.M.; Pithavala, Y.K.; Reich, S.D.; Freddo, J.L.; Wilding, G. 2005: Phase i trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(24): 5474-5483
Eskens, F.A.; Awada, A.; Cutler, D.L.; de Jonge, M.J.; Luyten, G.P.; Faber, M.N.; Statkevich, P.; Sparreboom, A.; Verweij, J.; Hanauske, A.R.; Piccart, M. 2001: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19(4): 1167-1175
Beeram, M.; Saif, M.W.; Sarantopoulos, J.; Schwartz, G.; Patnaik, A.; Tolcher, A.W.; Cheverton, P.; Kimura, M.; Danna, M.; Takimoto, C.H. 2016: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (D), and capecitabine (C) in patients (Pts) with advanced solid tumors Journal of Clinical Oncology 23(16_Suppl): 2037-2037
Minami, H.; Kawada, K.; Ebi, H.; Kitagawa, K.; Kim, Y.-i.; Araki, K.; Mukai, H.; Tahara, M.; Nakajima, H.; Nakajima, K. 2008: Phase i and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors Cancer Science 99(7): 1492-1498
Patnaik, A.; Warner, E.; Michael, M.; Egorin, M.J.; Moore, M.J.; Siu, L.L.; Fracasso, P.M.; Rivkin, S.; Kerr, I.; Litchman, M.; Oza, A.M. 2000: Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(21): 3677-3689